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Abstract
Background: Clostridium difficile (C. difficile) is a spore-forming, Gram-positive rod that is known to be associated with
antibiotic use. It is one of the leading causes of nosocomial diarrhea in the industrialized world and therefore warrants
further study of its nature. It isn’t clear if co-infection by other organisms can affect the outcome of C. difficile infection
(CDI).
Methods: A single center retrospective study was done and it used inclusion criteria of 18 years of age and being
tested positive for CDI on FilmArray® multiplex gastro-intestinal (GI) panel. Exclusion criteria were a GI panel performed on an outpatient basis, recurrent CDI, and the presence of end-stage renal disease, cirrhosis, or a non-GI
infection. The stool sample for all patients were collected within 48 h of presentation to the hospital. There were 235
of 2576 GI panels selected for a retrospective chart review based on the above criteria. Among these 235 patients,
38 had a co-infection (CDI+ another GI infection = group A or cases) and the rest had only CDI (group B or controls).
Group A was compared with group B for CDI severity, its response to treatment, recurrence, and length of the hospital
stay, using 0.05 as the alpha criterion.
Results: Most patients with CDI were female and above the age of 60 years. Co infection did not increase the severity
of CDI based both on the American College of Gastroenterology criteria (p 0.16) as well as Infectious Disease Society
of America criteria (p 0.77). Co infection group also didn’t have significantly different CDI related treatment failure rate
(p 0.23), or CDI recurrence rate (p 0.49). Co-infection was also not associated with lengthier hospital stay (p 0.41).
Conclusion: Our study suggests that co-infection doesn’t affect the severity of CDI or can cause treatment failures.
Additionally, there was no significant increase in hospital stay, or increase in CDI recurrence associated with coinfection. Therefore, if CDI is the leading clinical diagnosis and a patient is tested positive for co-infection in addition to
CDI on FilmArray® multiplex GI panel, this co-infection shouldn’t change the management for CDI. Limitations of this
study (including retrospective nature of the study, small sample size, single site study, not including all microbiome
and non-inclusion of race) should also be taken into account, while considering the applicability of the results of this
study.
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Background
Clostridium difficile infection (CDI) poses a major burden on the patient and the healthcare system by increasing mortality, morbidity, length of hospital stay, and costs
[1–3]. There has been a steady increase in the incidence
of CDI since 2000, with an associated increase in severity and poor clinical outcomes [4]. A European study
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showed that one in ten patients with CDI were either
transferred to the intensive care unit, underwent a colectomy, or died as a result of the infection [5]. This requires
further understanding of the pathophysiological and
clinical aspects of CDI, which might help physicians to
provide better care for patients with CDI, and it may also
reduce the burden on the health care system.

Methods
A single center retrospective study was conducted at
Saint Luke’s Hospital of Kansas City, MO—USA. Among
the 2576 FilmArray® multiplex gastrointestinal (GI) panels performed from January 1, 2015 to December 31,
2016, 235 patients were selected for chart review based
on the inclusion and exclusion criteria. Inclusion criteria included age of 18 years or above who tested positive
for Clostridium difficile (C. difficile) via the FilmArray®
multiplex GI panel. Exclusion criteria included GI panel
performed on an outpatient basis; recurrent CDI; and
patients with end-stage renal disease (ESRD), cirrhosis or
non-GI infection.
Selected patients’ population was divided into two
groups. Patients who had CDI as well as another GI
infection (co-infection) were placed into the case group
(group A). Patients who had CDI only were placed into
the control group (group B). Cases (co-infections or
group A) were then compared with controls (CDI only or
group B) to investigate the association between co-infection and CDI severity, its response to treatment, CDI
recurrence, and length of hospital stay. The Chi-square
test and Fisher’s exact tests were used to identify any statistical significance for severity, response to treatment,
and CDI recurrence, with an alpha criterion of 0.05. An

independent t-test was used to assess for any statistical
significance in the duration of hospital stay, with 0.05 as
the alpha criterion.

Results
Among the 235 patients selected based on the inclusion
and exclusion criteria listed above, 93 patients (39.57%)
were male and 142 patients (60.43%) were female. Two
patients (0.85%) were younger than 20 years of age,
13 patients (5.53%) were 20–29 years old, 24 patients
(10.21%) were 30–39 years old, 19 patients (8.09%) were
40–49 years old, 26 patients (11.06%) were 50–59 years
old, 47 patients (20%) were 60–69 years old, and 104
patients (44.26%) were 70 years old or above.
Among 235 patients, there were 38 cases (16.17%) and
197 controls (83.83%). Among the 38 cases (patients with
co-infection or group A), two patients had three infections at one time (C. difficile plus two other organisms).
The rest had only one more infectious agent besides C.
difficile.
The frequency of co-infection in cases was variable.
Enteropathogenic Escherichia coli (E. coli) was the source
of co-infection in 14 patients, norovirus in nine patients,
Campylobacter jejuni in five patients and enterotoxigenic
E. coli in three patients. Enteroaggregative E. coli, Salmonella and sapovirus were source of co-infection in two
patients each while enteroinvasive E. coli, Yersinia enterocolitica and adenovirus in one patient each.
There was no statistically significant difference in the
severity of CDI between the two groups based on the
American College of Gastroenterology (ACG) criteria
(p 0.16) as well as Infectious Disease Society of America
(IDSA) criteria (p 0.77) as shown in Figs. 1 and 2. There
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Fig. 1 Severity based on the criteria of American College of Gastroenterology (p-value = 0.16)
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Fig. 2 Severity based on the criteria of Infectious Disease Society of America (p-value = 0.77)

was no significant difference in treatment failure/escalation either between the two groups (p 0.23) as shown in
Fig. 3.
After enteropathogenic E. coli, norovirus was the
most common co-infection in this study. Its sub-set
analysis showed that among the nine patients with
norovirus co-infection, six were male and three were
women. Only two patients were below 60 years of age.
One patient with norovirus co-infection had severe
infection based on both IDSA and ACG criteria while
three other patient had severe infection based on IDSA

criteria only. Only one out of nine patients required
escalation of treatment. None of these nine patients
had recurrence of CDI. Among these patients, average
duration of hospital stay was 4.88 days, not significantly
different than for the whole group A (cases).
Likewise, there was no significant difference in C. difficile recurrence rate between the two groups (p 0.49) as
detailed in Fig. 4. The mean hospital stay for the patients
in case and control groups was comparable with no significant difference (p 0.41) between the two groups as
show in Fig. 5.
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Fig. 4 Clostridium difficile infection recurrence (p-value = 0.49)
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Fig. 5 Mean duration of hospital stay in days (p-value = 0.41)

Discussion
Many studies have investigated the factors that predispose patients to C
 DI3 and its recurrence after the initial
treatment [6]. Some recent studies have also investigated
the co-infection rate with CDI [7–9]. According to a multicenter evaluation of the BioFire FilmArray® GI panel
for etiologic diagnosis of infectious gastroenteritis [9],
at least one potential pathogen was detected in 53.5% of
the stool specimens that were collected, and among the
positive samples, 31.5% tested positive for more than one
potential pathogen. The samples that were co-infected
showed that CDI was present in 53.4% of them. Some
studies on pediatric population reported that CDI and
co-infection are associated with increased severity [10].
However, only a few studies on adult populations have
assessed the effects of co-infection on the severity of CDI
[10, 11] and other clinical outcomes [12].
Our study aimed to determine the burden and effects of
co-infection on CDI including CDI severity, its response
to treatment, CDI recurrence, and length of the hospital
stay in adult population.
We followed both ACG as well as IDSA criteria to
define the severity of CDI. This included a serum albumin < 3.0 g/dL plus either a white blood cell (WBC)
count ≥ 15,000 cells/mm3 or abdominal tenderness
for ACG severity criteria. Severity of CDI based on

the IDSA criteria was leukocytosis with a WBC count
> 15,000 cells/mm3 or a serum creatinine level ≥ 1.5 times
the premorbid level. Failure to respond to initial treatment was determined as any step up in the treatment
regimen. For example; if a patient was started on intravenous or oral metronidazole with no improvement of
symptoms and therefore was switched to oral vancomycin, was considered to be a failure of the initial treatment.
Similarly, patients requiring increase of vancomycin dose
or switch of oral vancomycin to oral fidaxomicin was
considered to be treatment failure or treatment escalation. Recurrence of CDI was defined as reappearance of
symptoms and being tested positive for CDI after a complete recovery of diarrhea for at least two weeks. Duration of hospital stay was measured in days for all patients
and was compared in both groups.
The idea behind using both the ACG and IDSA criteria to define severity was to allow the results to be interpreted in a more universal or generalized manner. We
also minimized the confounding variables as much as
possible. For example, in cirrhosis, albumin levels are
low and this affects the interpretation of severity based
on the ACG criteria. Thus, these patients were excluded.
Similarly, creatinine in patients with ESRD has less
meaning, but creatinine is part of the IDSA criteria for
severity. Thus, these patients were also excluded. Patients
with a concomitant non-GI infection were also excluded
because they cause an independent increase in the WBC
count and the WBC count is part of the severity criteria
for both ACG and IDSA. Recurrent CDI is more challenging to treat than the initial CDI [13]. Therefore, if a
patient with a recurrent CDI was to be compared to a
patient with an initial CDI, the treatment for the recurrent CDI would be more likely to fail and these patients
are expected to have a longer duration of hospital stay,
regardless of the presence of a co-infection, compared
with patients with an initial infection. To eliminate this
bias/confounding factor, all patients with recurrent CDI
were excluded and only patients with an initial CDI were
included.
Surprisingly, in contrast to the previous studies, our
results showed that co-infection in adult population
does not affect outcomes in terms of CDI severity, its
response to treatment, CDI recurrence, and length of
hospital stay. Colonization with certain pathogenic bacteria, such as E. coli, has been demonstrated in literature
at this point [14]. No objective data is available but it is
a possibility that the co-infections in our study represent
colonization or asymptomatic infections and they were
detected because of the higher sensitivity of polymerase
chain reactions employed by the FilmArray® multiplex
GI panel [9]. This information can help to prevent unnecessary treatment escalation in CDI patients if another
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co-infection is detected via FilmArray® multiplex GI
panel, especially if CDI is the leading clinical diagnosis.
Additionally, if such patient’s CDI worsens, it is less likely
to be the result of co-infection and an alternative cause
should be investigated.

Conclusion
If CDI is the leading clinical diagnosis and a patient is
tested positive for co-infection in addition to CDI on FilmArray® multiplex GI panel, this co-infection shouldn’t
change the management for CDI. Given additional limitations of this study as outlined below, careful consideration has to be given and further studies must be taken
in to account for sick patients (such as patients in intensive care units), patients with co-infection who are not
improving with treatment for CDI alone and patients
with additional co-morbidities (such as patients with
ESRD, cirrhosis, inflammatory bowel disease, patients on
chronic immune-suppressions or patients with human
immunodeficiency virus).
Limitations
Although efforts were made to minimize confounding
variables and evaluate the effects of co-infection on the
outcomes of CDI, there are still some limitations to this
study. This was a retrospective chart review study. So,
randomization could not be done and only reported outcomes were recorded. Due to our strict selection criteria,
the sample size was reduced to 38 patients having coinfection (cases) and therefore it didn’t include all microbiome. Race as demographic parameter wasn’t included.
Events only reported to our institute were recorded as it
was a single center study posing a risk of reporting bias.
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